NRIX insider transactions
Nurix Therapeutics Inc. (NRIX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for NRIX
- Chief Legal Officer Ring Christine exercised 3,422 shares at a strike of $1.86 and sold $135,253 worth of shares (8,148 units at $16.60) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 13,579 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Silva Paul M4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Saltzman Edward C4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Reinsdorf Judith A4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Nurix Therapeutics Inc.4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Nurix Therapeutics Inc.4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Dansey Roger D4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Baynes Roy D.4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Gregory Julia P4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Financial Officer Van Houte Hans sold $233,319 worth of shares (14,055 units at $16.60) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 37,592 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Legal Officer Ring Christine sold $138,210 worth of shares (8,148 units at $16.96) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 18,305 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Legal Officer Ring Christine sold $90,407 worth of shares (5,394 units at $16.76) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 26,453 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Financial Officer Van Houte Hans converted options into 8,608 shares and sold $39,749 worth of shares (2,388 units at $16.65), increasing direct ownership by 14% to 51,647 units (SEC Form 4) to satisfy withholding tax4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Legal Officer Ring Christine converted options into 8,608 shares and sold $53,498 worth of shares (3,214 units at $16.65), increasing direct ownership by 20% to 31,847 units (SEC Form 4) (for tax liability)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Scientific Officer Hansen Gwenn converted options into 8,608 shares and sold $53,498 worth of shares (3,214 units at $16.65), increasing direct ownership by 5% to 120,399 units (SEC Form 4) to satisfy withholding obligation4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Ring Christine4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Legal Officer Ring Christine sold $125,793 worth of shares (8,148 units at $15.44), decreasing direct ownership by 19% to 34,601 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Van Houte Hans4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Chief Legal Officer Ring Christine4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Hansen Gwenn4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by President, CEO Sands Arthur T4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Legal Officer Ring Christine sold $237,618 worth of shares (14,261 units at $16.66), decreasing direct ownership by 25% to 42,749 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Scientific Officer Hansen Gwenn exercised 31,333 shares at a strike of $0.84, increasing direct ownership by 37% to 115,005 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Financial Officer Van Houte Hans converted options into 11,496 shares and sold $60,767 worth of shares (3,661 units at $16.60), increasing direct ownership by 21% to 45,427 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Legal Officer Ring Christine converted options into 10,534 shares and sold $73,381 worth of shares (4,421 units at $16.60), increasing direct ownership by 12% to 57,010 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Scientific Officer Hansen Gwenn converted options into 11,816 shares and sold $81,249 worth of shares (4,895 units at $16.60), increasing direct ownership by 9% to 83,672 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Legal Officer Ring Christine exercised 3,760 shares at a strike of $1.86 and sold $69,273 worth of shares (3,760 units at $18.42) (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Legal Officer Ring Christine exercised 3,760 shares at a strike of $1.86 and sold $67,314 worth of shares (3,760 units at $17.90) (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Legal Officer Ring Christine sold $641,697 worth of shares (37,600 units at $17.07) and exercised 37,600 shares at a strike of $1.86 (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Dansey Roger D4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 3 filed by new insider Dansey Roger D3 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Financial Officer Van Houte Hans sold $78,931 worth of shares (6,284 units at $12.56), decreasing direct ownership by 14% to 37,592 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Financial Officer Van Houte Hans converted options into 11,494 shares and sold $40,054 worth of shares (3,130 units at $12.80), increasing direct ownership by 24% to 43,876 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Legal Officer Ring Christine converted options into 10,532 shares and sold $46,631 worth of shares (3,644 units at $12.80), increasing direct ownership by 16% to 50,897 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Scientific Officer Hansen Gwenn converted options into 11,815 shares and sold $52,300 worth of shares (4,087 units at $12.80), increasing direct ownership by 11% to 76,751 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Hansen Gwenn4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Director Gregory Julia P exercised 10,750 shares at a strike of $1.86 (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Financial Officer Van Houte Hans sold $59,598 worth of shares (5,402 units at $11.03), decreasing direct ownership by 13% to 35,512 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Legal Officer Ring Christine converted options into 10,532 shares and sold $46,134 worth of shares (3,841 units at $12.01), increasing direct ownership by 18% to 44,009 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Financial Officer Van Houte Hans sold $51,695 worth of shares (4,304 units at $12.01) and converted options into 11,494 shares, increasing direct ownership by 21% to 40,914 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Scientific Officer Hansen Gwenn converted options into 11,815 shares and sold $51,743 worth of shares (4,308 units at $12.01), increasing direct ownership by 12% to 69,023 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Silva Paul M4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Kunkel Lori Anne4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Gregory Julia P4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Saltzman Edward C4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Lacey David L.4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Kapur Anil4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Baynes Roy D.4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Reinsdorf Judith A4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Financial Officer Van Houte Hans sold $70,243 worth of shares (6,198 units at $11.33), decreasing direct ownership by 16% to 33,724 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Scientific Officer Hansen Gwenn converted options into 8,956 shares and sold $38,841 worth of shares (3,377 units at $11.50), increasing direct ownership by 10% to 61,516 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Legal Officer Ring Christine converted options into 7,674 shares and sold $33,286 worth of shares (2,894 units at $11.50), increasing direct ownership by 15% to 37,318 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Financial Officer Van Houte Hans converted options into 8,636 shares and sold $28,041 worth of shares (2,438 units at $11.50), increasing direct ownership by 18% to 39,922 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Director Baynes Roy D.4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 3 filed by new insider Baynes Roy D.3 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- Chief Financial Officer Van Houte Hans sold $84,388 worth of shares (5,825 units at $14.49), decreasing direct ownership by 15% to 33,724 units (SEC Form 4)4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by President, CEO Sands Arthur T4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Van Houte Hans4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Chief Legal Officer Ring Christine4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Hansen Gwenn4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)